Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deupirfenidone - Celea Therapeutics

Next Previous
Drug Profile

Deupirfenidone - Celea Therapeutics

Alternative Names: Deuterated pirfenidone; Deuterium-substituted pirfenidone; LYT-100; LYT-100-COV; LYT-100-ILD; LYT-100-LYMPH; Pirfenidone deuterated; SD-560

Latest Information Update: 31 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer PureTech Health
  • Class Anti-infectives; Anti-inflammatories; Antifibrotics; Organic deuterium compounds; Pyridones; Small molecules
  • Mechanism of Action Collagen inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • Discontinued Lymphoedema; Post acute COVID 19 syndrome

Most Recent Events

  • 22 Oct 2025 Updated adverse event data from the phase IIb ELEVATE IPF trial in Idiopathic pulmonary disease released by PureTech Health
  • 29 Sep 2025 Updated efficacy and adverse events data from a phase IIb ELEVATE IPF trial in Idiopathic pulmonary fibrosis released by PureTech
  • 17 May 2025 Adverse events data from a phase IIb ELEVATE trial in Idiopathic pulmonary fibrosis presented at the 121st International Conference of the American Thoracic Society (ATS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top